ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00360386|
Recruitment Status : Completed
First Posted : August 4, 2006
Last Update Posted : August 31, 2010
- To compare the Kinetics of inhibition of platelet aggregation (aggregometry) and platelet activation (flow cytometry) with different loading doses of clopidogrel
- To evaluate the effect on various parameters of inflammation and necrosis and the safety of these loading doses
|Condition or disease||Intervention/treatment||Phase|
|Ischemia||Drug: Clopidogrel||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||110 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis.|
|Study Start Date :||March 2004|
|Actual Primary Completion Date :||February 2005|
|Actual Study Completion Date :||February 2005|
- Maximum intensity of platelet aggregation induced by ADP 5 µmol/L.
- Kinetic profile by aggregometry. Kinetic profile of platelet activation by flow cytometry - Inflammation parameters/markers of necrosis. Death, myocardial infarction, ischemic recurrences leading to revascularisation and/or rehospitalisation.Safety.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00360386
|Study Director:||SAGNARD Luc||Sanofi|